Market Research Logo

Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)



Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease caused by the accumulation of a surfactant (proteins and lipids) accumulated in small air bags of the lung, called alveoli, which interfere with breathing. PAP condition occurs in 6 individuals per million and is considered an orphan disease.

Pulmonary surfactant is produced by the body in healthy people and patients with PAP, which is a mixture of phospholipids and synthesized proteins. These surfactants form cell lines to prevent the collapse of the pulmonary membranes by reducing the surface tension. This pulmonary surfactant must be constantly replaced to maintain the active and functional layer and to prevent excessive layering. The exact reason for the accumulation of excess surfactants is unknown. This requires a signal and messenger molecule called granulocyte-macrophage colony stimulating factor (GM-CSF) to stimulate alveolar macrophages to work properly and maintain a normal level of surfactant in the cells. This process of maintaining a stable state is known as homeostasis and requires that GM-CSF stimulate alveolar macrophages to remove excess surfactant.

Treatment of PAP depends on the form of PAP and age of a patient with PAP and severity of the disease. WLL is a standard treatment for PAP and the only treatment which has shown improved symptoms and oxygenation in patients. Another treatment of PAP includes using recombinant granulocyte colony stimulating factor (GM-CSF) which is given by nose or with a subcutaneous injection which is not approved yet.

The global PAP market is expected to show significant growth after the introduction of the molgradex drug in 2020. The growth of market will mainly be driven by huge unmet demand, increasing male population, rising middle-aged population and increasing health expenditure. However, the growth of the market will be hindered by the absence of effective diagnostics and costly drugs.

The report “Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of this market, with focus on the US, Europe, and Japan region. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. A key upcoming player in the market i.e. Savara Inc. is being profiled along with its key financials and strategies for growth. The report contains a comprehensive analysis of the global PAP market along with the study of the regional markets.


1. Market Overview
1.1 Pulmonary Alveolar Proteinosis (PAP)
1.2 Types of PAP
Table 1: Types of PAP (Pulmonary Alveolar Proteinosis)
1.3 Symptoms & Causes
1.4 Diagnosis
Table 2: Diagnosis of PAP (Pulmonary Alveolar Proteinosis)
1.5 Treatment
Table 3: Treatment of PAP (Pulmonary Alveolar Proteinosis)
2. Global PAP Market
2.1 Global PAP Market
2.1.1 Global PAP Patient Prevalence Forecast
Table 4: Global PAP Patient Prevalence Forecast (2017-2025)
2.1.2 Global PAP Prevalence by Type
Table 5: Global PAP Prevalence by Type (2016)
2.1.3 Global PAP Prevalence Forecast by Region
Table 6: Global PAP Prevalence Forecast by Region (2020)
2.2 Global PAP Market by Drug
2.2.1 Global Molgradex Addressable Population Forecast
Table 7: Global Molgradex Addressable Population Forecast (2017-2025)
2.2.2 Global Patients on Molgradex Therapy Forecast
Table 8: Global Patients on Molgradex Therapy Forecast (2020-2025)
2.2.3 Global Molgradex Revenue Forecast
Table 9: Global Molgradex Revenue Forecast (2020-2025)
3. Regional Market Analysis
3.1 The US
3.1.1 The US PAP Patient Prevalence Forecast
Table 10: The US PAP Patient Prevalence Forecast (2017-2025)
3.1.2 The US Molgradex Addressable Population Forecast
Table 11: The US Molgradex Addressable Population Forecast (2017-2025)
3.1.3 The US Patient on Molgradex Therapy Forecast
Table 12: The US Patient on Molgradex Therapy Forecast (2020-2025)
3.1.4 The US Molgradex Revenue Forecast
Table 13: The US Molgradex Revenue Forecast (2020-2025)
3.2 Europe
3.2.1 Europe PAP Patient Prevalence Forecast
Table 14: Europe PAP Patient Prevalence Forecast (2017-2025)
3.2.2 Europe Molgradex Addressable Population Forecast
Table 15: Europe Molgradex Addressable Population Forecast (2017-2025)
3.2.3 Europe Patient on Molgradex Therapy Forecast
Table 16: Europe Patient on Molgradex Therapy Forecast (2020-2025)
3.2.4 Europe Molgradex Revenue Forecast
Table 17: Europe Molgradex Revenue Forecast (2020-2025)
3.3 Japan
3.3.1 Japan PAP Patient Prevalence Forecast
Table 18: Japan PAP Patient Prevalence Forecast (2017-2025)
3.3.2 Japan Molgradex Addressable Population Forecast
Table 19: Japan Molgradex Addressable Population Forecast (2017-2025)
3.3.3 Japan Patient on Molgradex Therapy Forecast
Table 20: Japan Patient on Molgradex Therapy Forecast (2020-2025)
3.3.4 Japan Molgradex Revenue Forecast
Table 21: Japan Molgradex Revenue Forecast (2020-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Improving Global Economy
Table 22: Global GDP per Capita (2012-2016)
4.1.2 Rising Healthcare Spending
Table 23: Global Healthcare Spending Per Capita (2012-2016)
4.1.3 Rising Middle-Aged Population
Table 24: Global Middle-Aged Population (2012-2016
4.1.4 Increasing Male Population
Table 25: Global Male Population (2012-2016)
4.1.5 Huge Unmet Demand
4.2 Key Trends & Developments
4.2.1 Mergers and Acquisitions
Table 26: Mergers and Acquisitions (2016-2017)
4.2.2 Orphan Drug Designation
4.2.3 Increasing Awareness
4.2.4 Favorable Reimbursement Landscape
4.2.5 Limited Competition
4.3 Challenges
4.3.1 Expensive Alternative Procedures
4.3.2 Absence of Low-Priced and Effective Diagnostics
5. Competitive Landscape
5.1 Global Market
5.1.1 Global WLL Treatment Forecast
Table 27: Global WLL Treatment Forecast (2016-2025)
5.2 The US
5.2.1 The US WLL Treatment Forecast
Table 28: The US WLL Treatment Forecast (2016-2025)
5.3 Europe
5.3.1 Europe WLL Treatment Forecast
Table 29: Europe WLL Treatment Forecast (2016-2025)
5.4 Japan
5.4.1 Japan WLL Treatment Forecast
Table 30: Japan WLL Treatment Forecast (2016-2025)
6. Company Profiles
6.1 Savara Inc.
6.1.1 Business Overview
Table 31: Savara Inc. Products Under Pipeline (2016)
Table 32: Molgradex Clinical Study for aPAP (2016)
Table 33: IMPALA Trial Endpoints
6.1.2 Financial Overview
Table 34: Savara Inc. Revenue and Net Loss (2012-2016)
Table 35: Savara Inc. Estimated Revenue (2020-2025)
6.1.3 Business Strategies
Table 36: Savara Inc. Research & Development Expenses (2014-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report